Drugs / PF-06650808
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02129205 | Jun 2014 → Jul 2017 | breast cancer | Pfizer | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06650808 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02129205 ↗ |
| Modality | Other / unclassified | “anti-Notch3 antibody-drug conjugate (ADC)” PMID 30887250 ↗ Mar 2019 |
| Route | Intravenous | “PF-06650808 was administered intravenously every 3 weeks” PMID 30887250 ↗ Mar 2019 |
| Target | NOTCH3 | “anti-Notch3 antibody-drug conjugate (ADC)” PMID 30887250 ↗ Mar 2019 |